FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  SMITH IAN F				VI	2. Issuer Name and Ticker or Trading Symbol  VERTEX PHARMACEUTICALS INC /  MA [ VRTX ]									tionship of Reportin all applicable) Director Officer (give title		10% C			
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 03/23/2015								Λ	below) below) EVP & CFO					
50 NORTHERN AVENUE				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) BOSTON	N MA	Α (	)2210		_									X	Forn	Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
(City)	(St	ate) (	Zip)																
			e I - I					s A		ed, D	isposed o	-		cially					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		·	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			d 5) Securi Benefi		ficially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)			Transaction(s) (Instr. 3 and 4)			(Instr. 4)			
Common	Stock			03/23/20	)15				S <sup>(1)</sup>		200	D	\$122.4	<b>44</b> <sup>(2)(3)</sup>	1	23,976	D		
Common	Stock			03/23/20	)15				S <sup>(1)</sup>		200	D	\$123.5	52 <sup>(3)(4)</sup>	1	23,776	D		
Common Stock		03/23/20	15				S <sup>(1)</sup>		1,327	D	\$124.8	37 <sup>(3)(5)</sup>	1	22,449	D				
Common Stock		03/23/20	/2015				S <sup>(1)</sup>		2,815	D	\$125.0	125.69 <sup>(3)(6)</sup>		19,634	D				
Common	Stock			03/23/20	)15				S <sup>(1)</sup>		1,000	D	\$126.0	55 <sup>(3)(7)</sup>	1	18,634	D		
Common	Stock			03/23/20	)15				S <sup>(1)</sup>		500	D	\$127.8	33(3)(8)	1	18,134	D		
Common Stock														5,306	I	401(k)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	n Date Ex e (Month/Day/Year) if a		eemed ution Date, ch/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration (Month/Day			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		Deriv Secu (Inst	vative (urity 5	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amoun or Number of Shares						

## **Explanation of Responses:**

- 1. Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$122.44 (range \$122.10 to \$122.78).
- 3. Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$123.52 (range \$123.10 to \$123.93).
- 5. Open market sales reported on this line occurred at a weighted average price of \$124.87 (range \$124.28 to \$125.24).
- 6. Open market sales reported on this line occurred at a weighted average price of \$125.69 (range \$125.28 to \$126.24).
- 7. Open market sales reported on this line occurred at a weighted average price of \$126.65 (range \$126.29 to \$127.07).
- $8. \ Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$127.83 \ (range \ \$127.39 \ to \ \$128.19).$

## Remarks:

Omar White, Attorney-In-Fact 03/24/2015

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.